Abstract | PURPOSE: This study intended to determine the maximum tolerated dose, safety, pharmacokinetic variables, clinical response, and pharmacodynamic markers of daily s.c. administration of Angiozyme. PATIENTS AND METHODS: Patients with refractory solid tumors were enrolled in a dose escalation and expanded cohort design. Dose escalation involved cohorts of patients at doses of 10, 30, 100, or 300 mg/m(2)/d for 29 days. A second component enrolled 15 additional patients at a daily dose of 100 mg/m(2). Patients were eligible to continue on therapy until disease progression. RESULTS: Thirty-one patients were enrolled and 28 were evaluable (range, 29-505 days; median, 89.5 days). A maximum tolerated dose was not defined by toxicity but rather by the maximal deliverable dose of 300 mg/m(2)/d. Grade 1 to 2 injection site reactions were the most common toxicities. One patient in the 300 mg/m(2) group experienced a reversible grade 3 injection site reaction. Angiozyme showed dose-dependent plasma concentrations with good bioavailability. Surrogate markers showed Angiozyme localization in tumor biopsies and a significant increase in serum von Willebrand factor antigen, a marker for endothelial cell dysfunction. Although Angiozyme-reactive antibody production was noted for some patients, no antibody-related adverse events were noted. Seven of 28 (25%) evaluable patients had stable disease for >or =6 months, with the longest treatment duration of > or =16 months. Two patients ( nasopharyngeal carcinoma and melanoma) showed minor responses. CONCLUSION:
Angiozyme was well tolerated with satisfactory pharmacokinetic variables for daily s.c. dosing. Results have provided the basis for subsequent clinical trials of this first-of-class biologically targeted therapeutic.
|
Authors | David E Weng, Paul A Masci, Susan F Radka, T Elise Jackson, Patricia A Weiss, Ram Ganapathi, Paul J Elson, William B Capra, Vann P Parker, Jennifer A Lockridge, J Wayne Cowens, Nassim Usman, Ernest C Borden |
Journal | Molecular cancer therapeutics
(Mol Cancer Ther)
Vol. 4
Issue 6
Pg. 948-55
(Jun 2005)
ISSN: 1535-7163 [Print] United States |
PMID | 15956252
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiogenesis Inhibitors
- RNA, Catalytic
- von Willebrand Factor
- Vascular Endothelial Growth Factor Receptor-1
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors
(adverse effects, pharmacokinetics, therapeutic use)
- Female
- Humans
- Immunohistochemistry
- Male
- Middle Aged
- Neoplasms
(blood supply, drug therapy, genetics, pathology)
- RNA, Catalytic
(adverse effects, genetics, pharmacokinetics, therapeutic use)
- Treatment Outcome
- Vascular Endothelial Growth Factor Receptor-1
(genetics, metabolism)
- von Willebrand Factor
(metabolism)
|